Tizanidine Hydrochloride Capsule
Product Images NDC 71209-065

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 71209-065). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cadila Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tizanidine-spl-container-label-2mg-150cap (Tizanidine Spl Container Label 2mg 150cap)

Each capsule of the medication contains 2.2 mg of tizanidine hydrochloride, which is equal to 2 mg of tizanidine base. The medication should be stored at 25°C (77°F) and can be kept between 15° to 30°C (50° to 86°F). The usual dosage should be referred to the package insert for prescribing information. The medication should be dispensed in containers with child-resistant closures and kept out of the reach of children. Zanaflex®, the medication is a registered trademark of Acorda Therapeutics Inc. There are 150 capsules in each container. The medicine is manufactured by Cadila Pharmaceuticals Limited in Gujarat, India.*

FDA Label Image

Tizanidine-spl-container-label-4mg-150cap (Tizanidine Spl Container Label 4mg 150cap)

Each capsule of this medication contains 4 mg tizanidine base, equivalent to 4.58 mg tizanidine hydrochloride. It is recommended to store the capsules between 15°C to 30°C (50°F to 86°F) with excursions permitted. The package insert contains the usual dosage and prescribing information, and it must be dispensed in containers with a child-resistant closure. The medication should be kept out of children's reach, and Zanaflex is a registered trademark of Acorda Therapeutics Inc. The manufacturer of this medication is Caila Pharmaceuticals Limited in Gujarat, India.*

FDA Label Image

Tizanidine-spl-container-label-6mg-150cap (Tizanidine Spl Container Label 6mg 150cap)

FDA Label Image

Fig1 (Tizanidine Spl Fig 1)

FDA Label Image

Fig2 (Tizanidine Spl Fig 2)

FDA Label Image

Fig3 (Tizanidine Spl Fig 3)

This text presents the results of a study comparing the effectiveness of tizanidine and a placebo in reducing the Ashworth score in individuals. The study tracked the progress of participants up to Week 7, using a mean dose of 28.8 mg of tizanidine. The "End of Titration" point was at Week 3 and the "End of Maintenance Endpoint" was at Week 7. The results suggest that tizanidine may lead to an improvement in Ashworth score compared to a placebo.*

FDA Label Image

Structure (Tizanidine Spl Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.